Recurrent Acute Pancreatitis

Vishal Khurana¹, Ishita Ganguly²

¹Department of Gastroenterology, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India
²Department of Zoology, Ravenshaw University, Cuttack, Orissa, India

ABSTRACT

Recurrent acute pancreatitis (RAP) is commonly encountered, but less commonly understood clinical entity, especially idiopathic RAP, with propensity to lead to repeated attacks and may be chronic pancreatitis if attacks continue to recur. A great number of studies have been published on acute pancreatitis, but few have focused on RAP. Analysing the results of clinical studies focusing specifically on RAP is problematic in view due to lack of standard definitions, randomised clinical trials, standard evaluation protocol used and less post intervention follow-up duration. With the availability of newer investigation modalities less number of etiologies will remains undiagnosed. This review particularly is focused on the present knowledge in understanding of RAP.

Introduction

Inflammation of pancreas and/or peripancreatic tissue leads to acute pancreatitis (AP). Repeated episode of AP leads to recurrent acute pancreatitis (RAP) which has propensity to develop into chronic pancreatitis (CP). Development in understanding of RAP is hindered by lack of proper long term prospective follow-up, variability in period between attacks of pancreatitis, lack of standard guideline/algorithmic approach. Purpose of this review is to highlight present knowledge on RAP.

Relevant Anatomy

Pancreas, a vital gland derived from the foregut, having both exocrine and endocrine functions. In over 90% of individuals, dorsal pancreatic duct fuses with ventral pancreatic duct forming main pancreatic duct, thus pancreatic secretion drain through duct of Wirsung into duodenum by major duodenal papilla. However, 5-10% of healthy individuals have pancreatic divisum (PD) which is the most common pancreaticobiliary malformation [1,2]. In PD there is patent dorsal pancreatic duct, duct of Santorini, which opens into duodenum proximal to major papilla by minor duodenal papilla [3].

Literature Search

Literature review was performed by PubMed search (1948 through 30 Apr, 2014) for following terms: “recurrent acute pancreatitis,” “acute recurrent pancreatitis,” “recurrent pancreatitis” and “relapsing acute pancreatitis” in title/abstract. A total of 800 relevant articles dealing human species published in English language identified, out of which 496 articles were selected for critical review (Figure 1). All the articles dealing with the same research ideas were reviewed but those especially relevant to readers for review are quoted.

Definitions

The term “recurrent acute pancreatitis” was first used in medical literature by Henry Doubilet in 1948 [4], but the nomenclature was accepted during Marseilles symposium in 1963 [5]. It has been 50 years since the term accepted but still few is known about the entity. AP is an inflammatory process of pancreas with or without involvement of peripancreatic tissue or distant site. AP is clinically defined as the presence of two of the following features: pancreatic type pain, elevated serum lipase (or amylase) more than three times upper limit of normal and/or findings of AP with absence of changes characteristic of CP on cross-sectional abdominal imaging (contrast enhanced computed tomography or ultrasonography/magnetic resonance imaging) [6]. CP is said to be present when there is evidence of pancreatic duct change, pancreatic stone, fibrosis or calcification. There may be evidence of exocrine & endocrine insufficiency [7].

RAP is defined as more than one well documented & separate attacks of pancreatitis that completely or nearly completely resolved with more than three months in between the attacks [8-11]. Three months between the attacks is important because most of the sequel of previous attack of AP is present by the time. If the patient of AP redevelops pain abdomen with elevated pancreatic enzyme within three months, it may be due to some complication of first attack of AP and not RAP. If the pain recurs with initiation of feeding, it will be called as relapse of acute pancreatitis not RAP. Idiopathic RAP (IRAP) is defined as failure to disclose the discrete etiology of pancreatitis despite thorough history, routine laboratory, investigations (liver...
This rate depends on how aggressively cause of first attack is taken care off. A retrospective hospital based study of 1376 patients of AP done from 1975 to 1996 in Sweden by Andersson and colleagues found that 21% had recurrent attack of AP and 2/3rd had second attack within 3 months of index attack. Most common etiologies found in this study were cholelithiasis (35%) and alcohol (30%) [15]. Another hospital register study done in Sweden from 1988 through 2003 found that 16.9% had recurrent attack within one year of index AP, with recurrence rate of 9.4% in those who had biliary AP, 19.1% in alcoholic AP and 19.6% in those having etiology other than alcohol and biliary as cause [19]. Result of this study was strikingly in contrast to known recurrence rate of alcoholic AP of 46-50% and 33-60% in improperly treated biliary disease [10].

Most of the attacks of RAP are mild (95%) and mortality is 1%. Recurrence rate was maximum for AP due to pancreaticobiliary malformation (80%) with mean period between recurrences of 59.5 months, followed by alcoholic AP (recurrence rate of 36% and interval between attacks of 24.8 months), AP of unknown etiology (recurrence rate of 18% and interval between attacks of 9.6 months) and gallstone related AP (recurrence rate of 7% and interval between attacks of 12.3 months).

Previously it was believed that transition from AP to CP is very uncommon [20], however studies have shown this is not universal phenomenon [21]. Scarring caused by healing process after pancreatic necrosis causes pancreatic duct scarring as well as pancreatic pseudocyst, local complication of AP, is risk factor for RAP which can progress to CP [22]. Result from genetic studies, particularly hereditary pancreatitis, have shown that AP, RAP and CP are continuum of disease process if etiological factor persists [23-25]. If CP is etiological factor for RAP than features suggestive of CP are evident on imaging after 5 years of second attack of AP [20].

Figure 1. Literature review flowchart

function test, serum calcium, triglyceride level) and use of cross sectional abdominal imaging [11]. Term True IRAP (TIRAP) is used when discrete cause of pancreatitis could not be found even after extensive evaluation (i.e. after both level I and II evaluations, see below) [12]. Basic purpose of having such classification is to formulate stepwise plan to work up a patient of RAP, from limited evaluation (level I evaluation, see “approach” section below) first followed by extensive evaluation (level II evaluation). This will also maintain homogeneity among studies. Among studies which are performed on RAP, there is heterogeneity in definition of RAP and evaluation protocol used.

A question arise what is the need of differentiating acute from recurrent pancreatitis? Many studies have shown that most of the index attack of AP will not recur, so they need limited evaluation, but if the attack recurs (i.e. RAP) they needs detail evaluation as they may recur again [13,14].

Epidemiology

Exact incidence of RAP is difficult to estimate because of variation in geographical location, common etiology and evaluation approach used. Prevalence of RAP in various retrospective studies on AP varied from 10-30% [13-17]. In most studies male predominance is seen (male constitutes 63-79% of RAP cases) and the reason for this may be due to male preponderance for alcoholic acute pancreatitis (AAP) which has propensity to recur [13-18]. Mean age of RAP varies from 33 to 43 years [13-16,18].

Natural History

It is not known with utmost certainty that how many will have recurrent attack after an attack of AP? In various studies focusing this issue, approximately 10-30% of patients had repeat attack of AP; however there is heterogeneity in definition of RAP used, difference in common etiologies found and evaluation protocol used.
**Risk Factor for Recurrence**

It is important to know risk factors (RF) for recurrence of AP (Table 1), so that necessary action can be taken to curb it, to prevent repeat attack of AP. A retrospective urban study on AAP from Sweden found that mild index attack of AP is associated with high risk for recurrence [26]. Corollary to this finding a study on severe alcoholic necrotizing pancreatitis found low recurrence rate than mild AP [27].

In a retrospective study by Pelli and colleagues from Finland risk factors for the recurrence of AAP were young age (<45 years) at index AP, mild first attack of AAP and absence of pulmonary insufficiency [28]. However same author later published a prospective study of AAP and found pre-illness alcohol consumption, smoking and severity of index AAP were not associated with recurrence [29]. A study have shown persistent acute pseudocyst is associated with increased risk of recurrence rate, but further studies needed to establish firm association [30]. Improperly treated biliary disease is a risk factor of recurrence of biliary pancreatitis. Studies have shown recurrence rate of 33-60% if biliary pathology responsible for AP is not treated properly [31, 32]. Also there is definite risk of repeat attack of AP during waiting period for cholecystectomy [33]. It has been shown beyond doubt that gallstone related to AP should be treated with early (within 72 hrs) cholecystectomy (preferably laparoscopic) if the pancreatitis is mild and not to wait for normalization.

<table>
<thead>
<tr>
<th>Etiologies of RAP</th>
<th>Risk factors for recurrence of attack of AP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Established</strong></td>
<td>Alcohol [10, 13, 14, 18]</td>
</tr>
<tr>
<td></td>
<td>Hyperlipoproteinemia (hypertriglyceridemia) [44]</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hypercalcemia [45, 46]</td>
</tr>
<tr>
<td></td>
<td>Cholelithiasis/Choledochoolithiasis [10, 13, 14]</td>
</tr>
<tr>
<td></td>
<td>Hypercholesterolemia [47]</td>
</tr>
<tr>
<td></td>
<td>Ampullary or periampullary neoplasm [48-51]</td>
</tr>
<tr>
<td></td>
<td>Pancreaticobiliary anomaly (PD*, Choledochocoele, Anomalous pancreato-biliary junction, Annular pancreas) [10, 18, 52, 53, 54]</td>
</tr>
<tr>
<td></td>
<td>Sphincter of Oddi dysfunction [55]</td>
</tr>
<tr>
<td></td>
<td>Intraductal pancreatic mucinous neoplasm (IPMN) and other cystic neoplasm of pancreas [56-58]</td>
</tr>
<tr>
<td></td>
<td>Meandering main pancreatic duct [59]</td>
</tr>
<tr>
<td></td>
<td>Duodenal atresia or duplication cyst [60, 61]</td>
</tr>
<tr>
<td></td>
<td>Juxtapapillary diverticulum [62, 63]</td>
</tr>
<tr>
<td></td>
<td>Papillitis [64]</td>
</tr>
<tr>
<td></td>
<td>Crohn’s disease (Duodenal involvement) [65]</td>
</tr>
<tr>
<td></td>
<td>Hydatid cyst of the pancreas [66]</td>
</tr>
<tr>
<td></td>
<td>Wirsungocele/Santorinicele [67, 68]</td>
</tr>
<tr>
<td><strong>Mechanical</strong></td>
<td>Cystic fibrosis (CFTR mutation) [69]</td>
</tr>
<tr>
<td></td>
<td>Hereditary pancreatitis (PRSS1 mutation) [25]</td>
</tr>
<tr>
<td></td>
<td>SPINK1 mutation [69, 70]</td>
</tr>
<tr>
<td>Genetics</td>
<td>Azathioprine</td>
</tr>
<tr>
<td></td>
<td>Mercaptopurine</td>
</tr>
<tr>
<td></td>
<td>Asparaginase</td>
</tr>
<tr>
<td></td>
<td>Metronidazole</td>
</tr>
<tr>
<td></td>
<td>Sulphonamide</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
</tr>
<tr>
<td></td>
<td>Didanosine</td>
</tr>
<tr>
<td></td>
<td>Pentamidine</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
</tr>
<tr>
<td>Drug [71-76]</td>
<td>Estrogen</td>
</tr>
<tr>
<td></td>
<td>Furosamide</td>
</tr>
<tr>
<td></td>
<td>Thiazide</td>
</tr>
<tr>
<td></td>
<td>Salicylate</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen</td>
</tr>
<tr>
<td>Chronic pancreatitis [77]</td>
<td>Valproic acid</td>
</tr>
<tr>
<td>Infections</td>
<td>Ascariasis [78]</td>
</tr>
<tr>
<td><strong>Vascular</strong></td>
<td>Vasculitis (Systemic lupus erythematosus) [79]</td>
</tr>
<tr>
<td></td>
<td>Pancreatic Arterio-venous Malformation [80]</td>
</tr>
<tr>
<td><strong>Autoimmune pancreatitis</strong> [81]</td>
<td>Enzyme deficiency</td>
</tr>
<tr>
<td></td>
<td>Ornithine transcarbamylase deficiency [82]</td>
</tr>
<tr>
<td>Enzyme deficiency</td>
<td>Methylmalonyl-CoA mutase [83]</td>
</tr>
<tr>
<td></td>
<td>Propionyl-CoA carboxylase deficiency [84]</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>CFTR (cystic fibrosis transmembrane conductance regulator), SPINK1 (serine protease inhibitor Kazal type 1), PRSS1 (protease, serine, 1 [trypsin 1])</td>
</tr>
</tbody>
</table>

*Controversial etiological factor for RAP*
of serum pancreatic enzyme level or resolution of systemic inflammatory response syndrome (SIRS) [34,35]. In mild acute biliary pancreatitis, early cholecystectomy prevents the recurrence without increased operative difficulty compared to late cholecystectomy [36-38]. In case of severe acute gallstone pancreatitis, cholecystectomy to be done once patient is stable to undergo surgery or acute attack is over. Those who are at high risk for surgery can undergo endoscopic sphincterotomy [39]. If choledocholithiasis is the etiology of AP, then urgent ERCP to be done if there is cholangitis or impacted stone [40], otherwise patient will be subjected to ERCP once acute attack has subsided followed by cholecystectomy if gallstone is also there. A retrospective study of 245 patients of AP identified 77 by cholecystectomy if gallstone is also there. In an univariate analysis of 245 patients of AP identified 77 by cholecystectomy if gallstone is also there. In case of severe acute gallstone pancreatitis, cholecystectomy to be done once patient is stable to undergo surgery or acute attack is over. Those who are at high risk for surgery can undergo endoscopic sphincterotomy [39]. If choledocholithiasis is the etiology of AP, then urgent ERCP to be done if there is cholangitis or impacted stone [40], otherwise patient will be subjected to ERCP once acute attack has subsided followed by cholecystectomy if gallstone is also there. A retrospective study of 245 patients of AP identified 77 patients of RAP, with most common etiology being biliary (48 patient) [41]. In an univariate analysis of 245 patients authors found the presence of obstructive jaundice, liver enzyme derangement & local complication is significantly associated with recurrent AP with p value of <0.05 for each. However, on multivariate analysis none of the factor evaluated has shown to be associated with recurrence of AP. Limitation of this study is that they included patient who develop recurrence of the pain abdomen after refeeding as attack of RAP.

Recurrence in patients with AP due to other etiologies depends on how effectively the etiology has been treated. Surgical treatment of hypercalcemia in case of primary hyperparathyroidism prevents recurrence in AP but not in CP [42]. Recurrence of AP in hypertriglyceridemia can be prevented if serum triglyceride level is reduced to normal with diet and drugs [43].

**Etiology**

Various causes of RAP are described in Table 1. After reviewing thorough history (especially alcohol intake, trauma, family history & drug history), routine laboratory investigation & cross sectional imaging (level I evaluation) cause of RAP can be found in 70-90% [85]. Those who remain undiagnosed (IRAP; 10-30%) need extensive evaluation by level II investigation because it has been shown more than half of the patients of IRAP with continue to experience repeated attacks of pancreatitis and RAP is harbinger of CP [20].

As per North American Pancreatitis Study2 (NAPS2) study five or more drinks (in USA one drink is alcohol of 14 gms) per day for more than 5 years is considered as risk factor for CP [86]. There are more than 100 drugs implicated as cause of AP, continuous use may be associated with RAP [87]. A drug may be suspected as cause of pancreatitis if there is consistency latency between initiation of drug and onset of cause pancreatitis. Positive rechallenge may be a coincidental finding and is not always proof of association between drug and pancreatitis, recurrence of rechallenge may be due to microlithiasis or IRAP associated recurrent attack.

Common etiologies of RAP vary between studies depending on ethnicity, country of study, alcohol intake habit and methods used in evaluating the etiologies (Table 2). There is trend toward detection of more non-biliary etiologies. A retrospective study of AP done from 1990-1994 in 5 European countries by Gullo and coworkers found prevalence of RAP of 27% with alcohol (57%) being most common etiological factor followed by biliary pathology (25%) and idiopathic were 10% [13]. A study from China retrospectively evaluating the cause of RAP from 1992-2002 found idiopathic being most common followed by alcohol and biliary being 20% each [14]. A recently published study by Takuma & colleagues from Japan evaluating the causes of RAP vs nonrecurrent AP found alcohol (38%) as most etiology of RAP and gallstone (36%) as most common etiology in nonrecurrent AP [10]. A prospective study by Sherman & co-worker evaluating 55 IRAP patients with ERCP, SOM and bile microscopy showed detection of SOD in one third patients, pancreatic divisum in 14% and microlithiasis in 12%; one third patients still remained undiagnosed after these investigations. Response rate to endotherapy or surgical therapy was 84% in follow up period of 17 months, but 54% patients also showed response to no therapy [88].

A retrospective tertiary care hospital based study of RAP from South India found biliary cause in most patients (37%) followed by idiopathic (27%) and alcohol (6.4%) [18]. Another tertiary care hospital based study from North India which prospectively evaluated patients of IRAP with ERCP, EUS or bile microscopy showed that 46% patient had some evidence of CP on imaging; microlithiasis and pancreatic divisum were present in 13% and 5.3%, respectively. One fourth patients remained idiopathic after application of these three investigations. Mean follow up duration was 17.6 months, most patients had mild attack and mean number of attacks was 4.82 [47].

**Sphincter of Oddi (SO) Dysfunction (SOD)**

Postulated mechanism of role of SOD in pancreatitis is by causing obstruction to flow of pancreatic juice by narrowed Sphincter of Oddi (SO stenosis) or functional obstruction (SO dyskinesia) [89]. There has been much debate whether SOD is a cause of RAP but there are ample evidences available in favor of its role in RAP [90]. Firstly, studies using sphincter of Oddi manometry (SOM) for RAP have shown SOD (defined as basal sphincter SO pressure >40mmHg) is present in 15-72% of IRAP [88, 91-97]. Secondly, recurrence rate of RAP after endoscopic sphincterotomy reduced by 60-95% [88, 94-96, 98-101]. Studies have shown that it is pancreatic SOD which correlates with elevated pancreatic ductal pressure and pancreatitis whereas biliary SOD correlates with biliary pain and elevated aminotransferases. Biliary sphincter manometry miss 10-35% of pancreatic SOD so pancreatic SOM is recommended technique in evaluation of IRAP instead of biliary SOM alone [91, 102, 103]. Only patients who have abnormal pancreatic SOM should be subjected to sphincterotomy due to high risk of relapse if normal manometry and high risk of post-ERCP pancreatitis. Studies have shown that performing biliary sphincterotomy...
do decrease recurrence rate of RAP, this is mainly due to cutting sphincter of common channel which will also reduced residual pancreatic sphincter length thereby reducing basal pancreatic sphincter pressure. A long term (≥10 years) follow up study by Wehrmann prospectively evaluated patients of RAP with SOD who underwent endoscopic sphincterectomy and found that 14% patients had recurrence of pancreatitis in first two year of follow up, however they responded to dual endoscopic sphincterotomy or surgical pancreaticojunostomy [101].

**Pancreatic Division (PD)**

PD is the most congenital anomaly of pancreas present in 5-10% of healthy population [1]. There are two schools of thought regarding its role in RAP: proponents argue that PD is causative factor for RAP by causing functional obstruction to pancreatic secretion [104, 105]. Evidences in favor of PD’s role in RAP are many. Firstly, Studies have shown elevated pancreatic ductal pressure in patients with PD versus that don’t have PD [106]. Secondly, widening of minor papilla by endoscopic pancreatic sphincterotomy or surgical sphincteroplasty have shown to decrease risk of recurrence of AP [107, 108]. Thirdly, retrospective studies have shown statistically significant high prevalence of PD in RAP cases [109]. Fourthly, a cross sectional study by Gonoi and colleagues found unbiased statistically higher prevalence of PD in IRAP cases (33%) compared to community dwelling subjects (2.6%) by MRCP [110].

However newer studies are revealing that PD itself doesn’t cause RAP. Most of studies on PD in RAP are retrospective. Some authors argue that detection of PD in RAP may be coincidental finding [111, 112]. A recent study by Bertin and co-workers evaluated the frequency of PD by MRCP in subjects of IARP and simultaneously evaluated for genetic mutation, found no increase prevalence of PD in IRAP as compared to healthy subjects or patients with alcohol-related pancreatitis however the prevalence of PD increased in patients with CFTR gene mutations [113]. Other studies have also found high prevalence of genetic mutation in patient of RAP who also had PD. So new school thought argues that it is genetic mutation act as cofactor in patient with PD to cause RAP.

**Genetic Factors in RAP**

Since the description by Whitcomb regarding genetic mutation in pancreatitis multiple studies have shown the association of various genetic mutations in susceptible genes & modifier genes as mechanism of RAP [114-116]. Prevalence of genetic mutations in children with IRAP is high [115-118]. Common genetic mutations shown to have role in RAP are CFTR (cystic fibrosis transmembrane conductance regulator), SPINK1 (serine protease inhibitor Kazal type 1) and PRSS1 (cationic trypsinogen). These mutations make pancreas susceptible to RAP by retarding protection against insult. These mutations are also seen in patients with anatomic variants (PD) and metabolic disorders (hypertriglyceridemia and hyperparathyroidism) which predispose a person to RAP, suggesting a major role of these mutations plays in RAP. Patients usually present in young age with RAP and subsequently have features to CP after many years depending on mutation. A retrospective study from Italy by Lucidi and coworkers evaluated etiological cause in 78 children with IRAP by ERCP, sweat chloride analysis and mutation analysis found positive family history in 20.5%, abnormal sweat chloride analysis in 10.3%, biliary lithiasis in 6.5% and mutation in susceptibility genes in 51.2% (CFTR 39.6%, SPINK1 7.1% and PRSS1 in 4.5%) [118]. As of now testing for genetic mutation in clinical practice is limited for PRSS1 gene in hereditary pancreatitis as it is autosomal dominant with high penetrance and predispose a person to pancreatic malignancy, rest of predisposing genes are tested for research purpose only. A review suggested to perform PRSS1 testing in IRAP first, then to test CFTR if PRSS1 negative and SPINK1 if both PRSS1 and CFTR negative [119, 120]. Genetic testing will be beneficial especially in patients of younger age and RAP, but it will not help in planning treatment but just help establishing cause-effect relationship and prognosticating patient for likely development of CP/pancreatic adenocarcinoma in future. Lack of long term follow-up studies hinders proper understanding of role genetic factors plays as first attack of pancreatitis may be just an attack of AP (genetic or non-genetic) or first presentation of CP, and attacks of RAP may be separated by months to years of pain free period.

**Microlithiasis and Biliary Sludge**

Microliths are defined as stone <3mm in size made of whereas biliary sludge is mixture of calcium carbonate microspheroliths, calcium bilirubinate granules and amorphous cholesterol monohydrate crystals suspended in layer of mucus, glycoprotein and cellular debris [121]. Microliths, by virtue of its size and ability to travel from

Table 2. Etiological studies of RAP over 10 years.

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Study period</th>
<th>Study design</th>
<th>Mean age ± SD (range)</th>
<th>Most common etiology</th>
<th>2nd Most common etiology</th>
<th>3rd Most common etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sajith et al. [18] (2010)</td>
<td>188/...</td>
<td>Jan 1975-Dec 2010</td>
<td>Retrospective</td>
<td>33 yrs</td>
<td>Biliary (37%)</td>
<td>Idiopathic (32%)</td>
<td>PD (6.5%)</td>
</tr>
<tr>
<td>Takuma et al. [10] (2012)</td>
<td>74/381</td>
<td></td>
<td>Retrospective</td>
<td>50.1 ± 18.5 yr</td>
<td>Alcohol (38%)</td>
<td>Idiopathic (26%)</td>
<td>Alcohol (6.4%)</td>
</tr>
</tbody>
</table>
gallbladder to duodenum with ease, can obstruct the ampulla leading to AP and repeated attacks leads to RAP; also as result of repeated trauma to papilla by stone there is papillary stenosis and development of SOD. Many evidences in support of its role in RAP exist. Firstly, it occurs with increased prevalence in RAP (60-73% prevalence in IRAP patients using bile microscopy), particularly in noncholecystectomised patients compared to healthy individuals [88, 196, 122-124]. Secondly, recurrent attack of AP almost eliminated post—cholecystectomy [122-124]. Sensitivity for diagnosis of microliths and biliary sludge is 50-60% by US [122, 125, 126], 65-90% by microscopic bile examination (MBE) [126-131], and 92.6% by EUS [132-134]. It was a common practice to assume the presence of bile crystal by bile microscopy as microlithiasis but both are different entity. Bile crystal themselves does not cause pancreatitis. Previous studies have used MBE as gold standard for diagnosis of occult gallstone disease but this has been largely replaced by EUS which has equivalent accuracy for diagnosis as well as ability to diagnose of other etiologies. Recent studies on IRAP which have used EUS instead of bile microscopy have reported low prevalence (13%) of microlithiasis as a cause of IRAP then what was reported for positive bile microscopy [47]. Ideal situation to label microlithiasis as cause of RPA would be detection of microliths by EUS and presence of elevated aminotransferases within first 24 hrs of development of pancreatitis. Another point to be noted also that patients who have long history of RAP and detected to be microliths, microlithiasis is hard to be attributed as cause of RAP as microlithiasis will not remain micro for years. Microliths is not an attributable factor for RAP in cholecystectomised patients [96,98].

**Approach to Diagnosis**

Recent medical advances have improved our understanding of diagnosis and management of RAP. There is no recommended algorithm by any pancreatitis body for evaluation of RAP; proposed algorithm is presented in Figure 2.

When a patient of RAP (RAP) presents initially should be subjected to level I evaluation (Tables 3 and 4) consisting of thorough history taking (especially alcohol, trauma, drug and family history), biochemistry evaluation (liver function test, serum calcium, and lipid profile) and cross-sectional imaging by ultrasound or pancreatic protocol CT. Pancreatic protocol CT can detect changes suggestive of CP and also pancreatic cystic or solid neoplasm which could be missed on USG. If etiology could not be found after level I evaluation patient are labelled as having IRAP and need level II evaluation. Level II evaluation includes laboratory

---

**Figure 2.** A. Overview of evaluation plan for RAP, B. Proposed algorithm for evaluation of a case of RAP.
test (genetic studies, bile microscopy), MRCP/ MRCP-S, EUS/EUS-S with or without fine needle aspiration (FNA) or ERCP (with or without bile aspiration, sphincter of Oddi manometry, secretin test, intraductal US). Rationality of using this two-tier approach is because specific cause of RAP can be found in 70-90% of cases by level I evaluation only, so need not to subject patients to costly and less readily available investigations [85, 135, 136]. This approach has been used in many studies addressing RAP [47].

However, even after extensive evaluation (level I & II evaluation) few patients remain undiagnosed and they are called as TIRAP. This group of patient should be subjected to repeat serum calcium and triglyceride, serum immunoglobulin G4 levels (for autoimmune pancreatitis) or pancreatic function test (to detect early CP). Many of these patients will develop features of CP which could be detected in follow-up cross-sectional imaging (CT/ MRI); this group of patients might be having early CP not detectable on initial imaging or RAP progressed to CP in due course of time as a result of repeated injury [47]. There is no definite recommendation from any investigator when and how to follow patients of TIRAP.

Bile Microscopy
Detection of calcium bilirubinate, cholesterol monohydrate, or calcium carbonate crystals can be done by obtaining bile from duodenum or bile duct using endoscopy, ERCP, or EUS than centrifuging and examination under light or polarising microscope [137]. Intravenous administration of 0.02–0.04 ng/kg of cholecystokinin can aid the detection rate. Bile microscopic examination has role in patient with intact gallbladder not in cholecystectomised patients.

**EUS (EUS-S) for RAP**

Introduction of EUS has revolutionised the diagnostic approach of RAP because of its ability to detect even little changes in duct or parenchyma, before manifesting in cross-sectional imaging, thereby suggesting diagnosis of CP. EUS should be considered as investigation of choice in a patient of IRAP since it is less invasive than ERCP, highly accurate and many other procedures can be done if needed like duodenal bile aspiration, fine needle aspiration, trucut biopsy, endoscopic pancreatic function test, and provide noninvasive assessment of SOD. A prospective study by Ortega and co-workers comparing EUS and MRCP in IRAP cases found EUS to be more useful in reaching etiological diagnosis with diagnostic yield of 51% for EUS and 20% for MRCP (P=0.001). However EUS had less diagnostic yield in cholecystectomised cases [138].

Yusoff and colleagues in their study using EUS in patients of idiopathic AP and IRAP in no cholecystectomy and post cholecystectomy patients found positive EUS finding in 31.3% in idiopathic AP and 32.1% in IRAP patients (p=0.89) whereas in post-cholecystectomy patients positive findings were present in 29.9% and 17.5% in AP and RAP patients,
respectively (p=0.15). Addition of bile microscopy, in no cholecystectomy group if normal EUS finding, yielded positive finding in 20/43 (46.5%) RAP patients [139].

Secretin-stimulated EUS (EUS-S), done after 1 IU/kg i.v bolus of secretin injection, enhances pancreatic duct morphology which is especially useful in nondilated system. Also, addition of secretin, which increases pancreatic secretion leading to transient dilatation of pancreatic duct in normal subjects, help in real time assessment of pancreatic flow dynamics, so functional impairment can also be seen which is regarded as surrogate noninvasive marker of SOD [140].

A study evaluating the correlation between EUS finding and pancreatic function test by endoscopic collection of duodenal sample for bicarbonate levels in patient with suspected early CP changes, found moderate negative correlation and 76% concordance rate between the finding on EUS and peak bicarbonate level [141].

**MRCP (MRCP-S)**

MRCP is an excellent tool for assessment of ductal morphology. Secretin stimulated MRCP (MRCP-S) increase the diagnostic yield by better delineating ductal morphology in otherwise nondilated pancreatic ducts and ability to detect pancreatic functional outflow obstruction [142]. It is performed by intravenous administration of 1 IU/kg of secretin, and persistence of main pancreatic duct dilatation of >1mm between baseline and 15 minutes is taken as noninvasive marker of SOD. Mariani and co-workers compared MRCP-S and SOM for evaluation of SO function in patients with IRAP and found concordance rate of 86.7% between both tests, and agreed positive and negative diagnoses in 81.8% and 100%, respectively [143]. Another study comparing MRCP-S versus ERCP with SOM in 37 IRAP patients with non-cholecystectomised nondilated pancreatic ductal system found sensitivity, specificity, positive predictive and negative predictive value for pancreatic outflow obstruction were 57.1%, 100%, 100%, and 64%, respectively [144]. MRCP-S also help in quantitative assessment of pancreatitis reserve exocrine function and it correlate significantly with fecal elastase-1 levels, which is marker of pancreatic exocrine function, thereby it can help in diagnosis of early CP even if there is no structural change suggestive of CP on imaging [145].

**ERCP in RAP**

With the advances in pancreaticobiliary imaging and availability of EUS, ERCP is rarely used now-a-days for diagnostic purpose only except for sphincter of Oddi manometry (SOM) and intraductal US. Main advantage of ERCP over MRCP or EUS is the ability to perform therapeutic measures in the same session of procedure if abnormality detected. Coyle and colleagues in their study in 66 patient of IRAP by EUS and ERCP with bile microscopy and SOM found positive yield in 79% cases, SOD being the most common etiology (30%) [95]. A prospective study by Kim and co-workers in 31 IRAP patients with normal ERCP findings found possible cause of RAP in 42% patients by addition of intraductal US [146]. Finding being microlithiasis (16.1%), biliary sludge (9.7%), features of CP (9.7%) and distal pancreatic duct polypoidal lesions (6.5%). A prospective study compared EUS-S, MRCP-S and ERCP in evaluation of 44 consecutive IRAP patients with non-dilated ducts and found highest diagnostic yield for EUS-S i.e. 79.6% followed by MRCP-S 65.9% and ERCP 62.8% [147].

**Pancreatic Function Testing (PFT)**

Many patients of IRAP have CP either on evaluation by EUS/ MRCP/ERCP or they may develop evidence of CP in follow up thereby indicating that these patients might be have subtle evidence of CP from the very beginning which might be responsible for recurrent attacks of pancreatitis or they may develop CP as a result of repeated insult to pancreas by RAP [47]. In PFT, duodenal aspirate is collected for estimation of bicarbonate concentration.
after intravenous secretin injection [148]. PFT is the most sensitive test for evaluation of early evidence of CP. So it will be prudent to subject the patients of IRAP to EUS followed by pancreatic function testing (if EUS is normal), so that CP will be detected early. Combination EUS with PFT give 100% sensitivity for diagnosis of CP [149].

**Treatment**

Management of acute attack of RAP is similar to standard treatment guidelines of AP with nil per mouth, intravenous hydration, adequate analgesia, correction of electrolyte or metabolic abnormalities and proper treatment of complications of AP. If a specific cause pertinent to RAP is ascertained than specific therapy is directed to that etiology: cessation of alcohol intake and smoking [150], cholecystectomy/ES/ERCP, stoppage intake of offender drug, parathyroidectomy and hypolipidemic drugs if alcohol, gallstone/choledocholithiasis, drug, hypercalcemia due to primary hyperparathyroidism and hypertriglyceridemia are responsible factor for RAP, respectively.

Role of endotherapy for patient of RAP with pancreatic divisum (PD) is still controversial. Studies which had shown role of endotherapy (minor papilla sphincterotomy or stenting) or surgery (sphincteroplasty) are mainly retrospective with less mean follow up period [108,113,151-162]. In a systematic review on endotherapy and surgical treatment for PD found not statistically different pooled response rate of 79.2 and 83.2% for endotherapy and surgery, respectively [163]. Recent study by Rustagi and co-worker shown response rate of 94% in patient of PD with RAP [164] It has always been argued whether the benefit of ES in PD is true phenomenon or placebo effect as the interval between attacks of RAP can vary from months to many years [165,166]. In carefully selected patients with PD, endoscopic minor papilla sphincterotomy and/or stent insertion (for short term unflanged stent preferred to aid spontaneous stent migration) can relieve the obstruction to pancreatic juice flow.

Most of the studies on RAP with SOD have recommended dual sphincterotomy as treatment of choice [91,100,101,102], however these studies were nonrandomised and all study except Wehrmann had follow up of less than 2 years. Recent randomised control trial by Cote and coworkers have shown similar efficacy for biliary endoscopic sphincterotomy and dual endoscopic sphincterotomy with recurrence rate of 47% and 49% for biliary and dual endoscopic sphincterotomy, respectively, during follow up of 1-10 years [11].

Patient of microlithiasis should be subjected to laparoscopic cholecystectomy if good operative candidate or ES and/or UDCA can be used as alternative for elderly patients, poor operative candidates or unwillingness for surgery [85,123,167,168]. In study conducted by Saraswat and colleague showed positive bile microscopy in 74% patients of IRAP and all patients who underwent cholecystectomy or ES remained asymptomatic for mean follow up of 23months (range 6–48 months) and 90% patients on UDCA remain asymptomatic for more than 9 months [168].

There is no validated therapy for TIRAP patients. Treatment usually offered to TIRAP patients includes laparoscopic cholecystectomy, ES or UDCA. However recent study has raised doubt on this practice [169]. A study by Trna and colleagues evaluated the role of cholecystectomy in idiopathic pancreatitis or presumed gallstone related pancreatitis revealed that absence of elevation of liver enzymes on day 1 of AP or absence of gallstone/sludge on US were associated with increased risk of recurrence of AP [170].

Antioxidants have no beneficial effect in RAP. Morris-Stiff GJ and colleagues compared the levels of trace elements (selenium, copper, zinc), vitamins A and E, and carotenoids (alpha-carotene, beta-carotene, xanthine, beta-cryptoxanthine, lycopene) among normal, RAP and CP found that levels of these antioxidants was statistically different between normal and CP but not in normal versus RAP [171].

**Conclusion**

RAP is common but still a misunderstood disease. Interpretation of results of available studies is hampered by lack of standard definition and evaluation protocol used. Also analysing the results of endotherapy/surgery for various etiology of IRAP is also hindered by lack of significant follow up period. With the advancement and availability of investigations to diagnoses less common causes of pancreatitis, fewer patients are left idiopathic.

**Source of Support/Fund**

No funding source was involved in the preparation of this paper or in the decision to submit it for publication.

**Author Contributions**

Vishal Khurana did (a) searching the literature, (b) conception and design or analysis and interpretation of the data, (c) the drafting of the article or critical revision for important intellectual content, and (d) final approval of the version to be published. Vishal Khurana and Ishita Ganguly was involved in writing and editing of this manuscript.

**Conflicting Interest**

The authors have no conflicts of interest.

**References**


136. Baille J. What should be done with idiopathic recurrent acute pancreatitis that remains idiopathic after standard investigation? JOP. 2001; 2:401-406. [PMID:11886699]


